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Summary
X-linked ocular albinism (OA1), Nettleship-Falls type,
is characterized by decreased ocular pigmentation, fo-
veal hypoplasia, nystagmus, photodysphoria, and re-
duced visual acuity. Affected males usually demonstrate
melanin macroglobules on skin biopsy. We now report
results of deletion and mutation screening of the full-
length OA1 gene in 29 unrelated North American and
Australian X-linked ocular albinism (OA) probands, in-
cluding five with additional, nonocular phenotypic ab-
normalities (Schnur et al. 1994). We detected 13 intra-
genic gene deletions, including 3 of exon 1, 2 of exon
2, 2 of exon 4, and 6 others, which span exons 2–8.
Eight new missense mutations were identified, which
cluster within exons 1, 2, 3, and 6 in conserved and/or
putative transmembrane domains of the protein. There
was also a splice acceptor–site mutation, a nonsense mu-
tation, a single base deletion, and a previously reported
17-bp exon 1 deletion. All patients with nonocular phe-
notypic abnormalities had detectable mutations. In sum-
mary, 26 (∼90%) of 29 probands had detectable alter-
ations of OA1, thus confirming that OA1 is the major
locus for X-linked OA.
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Introduction
X-linked Nettleship-Falls ocular albinism (OA1; MIM
300500) typically results in severely impaired visual acu-
ity in affected males (Nettleship 1909; Falls 1951;
O’Donnell et al. 1976, 1978a). Similar to individuals
with oculocutaneous forms of albinism, males with oc-
ular albinism (OA) have infantile nystagmus, photodys-
phoria, variable strabismus, and misrouting of optic
pathways (Creel et al. 1978), with asymmetrical occip-
ital visual evoked potentials and accentuated electro-
retinographic changes (Russell-Eggitt et al. 1990). Het-
erozygotes usually demonstrate a pattern of mosaic
retinal pigmentation and iris transillumination that is
assumed to represent the direct effects of random X in-
activation (Falls 1951; Lyon 1962; O’Donnell et al.
1976; Charles et al. 1992). With rare exceptions (e.g.,
see Pearce et al. 1972; Jaeger and Jay 1981), most het-
erozygotes do not have nystagmus or reduced visual
acuity.
X-linked OA is also characterized by the presence of
giant pigment granules or melanin macroglobules
(MMGs). MMGs probably represent autophagolyso-
somes that contain melanosomes (Nakagawa et al.
1984) and may be detected, by both light microscopy
and electron microscopy, in the skin and retinal pigment
epithelium (RPE) of almost all affected males and of
many obligate heterozygotes (O’Donnell et al. 1976;
Charles et al. 1992). MMGs distinguish X-linked OA
from autosomal recessive forms of OA (O’Donnell et al.
1978b) and from other X-linked disorders of ocular pig-
mentation that are associated with cone and rod dys-
function (e.g., see O’Donnell et al. 1980). In the Che-
diak-Higashi and Hermansky-Pudlak syndromes, there
are disturbances in other melanolysosomal structures,
which result in additional nonocular abnormalities, such
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as immunodeficiency or platelet storage–pool deficiency.
In X-linked OA, however, morphological abnormalities
(e.g., the giant pigment granules) are limited to the skin
and RPE and correlate with the more restricted clinical
phenotype.
The OA1 gene was recently identified by positional
cloning (Bassi et al. 1995), and its genomic organization
was defined (Schiaffino et al. 1995). The gene product
has no known homology to other proteins, and its func-
tion is unknown. On the basis of a comparison of the
region of homology between humanOA1 and its murine
homologue, Schiaffino et al. (1995) proposed that the
second in-frame ATG of the original published sequence
is the authentic initiation codon. From this site, the tran-
script encodes a protein of 404 amino acids with several
possible transmembrane domains. As expected, the
gene’s expression pattern is restricted mainly to pigment
cells of the skin and eye. Surprisingly, Schiaffino et al.
(1995) detected mutations in only one-third of a patient
group studied.
Using published OA1 cDNA and genomic-sequence
information (Bassi et al. 1995; Schiaffino et al. 1995),
we screened a group of 29 unrelated X-linked OA pa-
tients from North America and Australia (table 1), for
mutations. Among this group are two families in which
affected males lack the characteristic MMGs, five ped-
igrees that contain possibly manifesting females (one
with a 45,XO karyotype), and five probands who have
additional, nonocular phenotypic abnormalities (sum-
marized in Schnur et al. 1994). Previous studies detected
no evidence for either genetic heterogeneity (by linkage
analysis) or large deletions around the OA1 locus, with
flanking genetic markers in these families. We report the
detection of OA1 mutations in the majority of our study
group and thus verify that OA1 is the major gene locus
for X-linked OA.
Subjects, Material, and Methods
Subjects
Clinical features and linkage data for many of our OA
subjects and their pedigrees have been reported else-
where (Schnur et al. 1989, 1990, 1991, 1993, 1994).
OAP-8 initially was reported by Reichel et al. (1992),
and OAP-12 initially was reported by Kidd et al. (1985).
Each proband had typical ocular findings of the disease,
and at least one female within each family either was
documented to be an obligatory carrier or displayed typ-
ical fundascopic findings of a heterozygote and/or biopsy
findings (i.e., MMGs). Unusual phenotypic features and
the results of skin biopsies, when performed, are sum-
marized in table 1.
DNA was extracted directly from either whole blood
or cultured lymphoblastoid cells of OA probands and
available family members, by standard techniques (Al-
dridge et al. 1984). This study was approved by the
institutional review boards of the Children’s Hospital of
Philadelphia, the University of Pennsylvania School of
Medicine, and the Cooper Hospital/University Medical
Center.
Source of cDNA and Genomic Probes
Pooled lysate DNA from a retinal cDNA library (Na-
thans et al. 1986) was used as template for PCR am-
plification, with combinations of either previously pub-
lished primers or new primers designed on the basis of
the published cDNA sequence of OA1 (Bassi et al.
1995). PCR products were gel purified for direct use as
hybridization probes and for selective cloning into the
TA cloning vector (Invitrogen). Genomic probes for in-
dividual exons were generated by gel purification of PCR
amplification products, with genomic DNA as template
for previously published primers (Bassi et al. 1995;
Schiaffino et al. 1995).
Mutation Analysis
Southern blot analysis for deletions.—DNA samples
from probands were subjected to cleavage with TaqI and
PstI and were resolved by gel electrophoresis. Southern
blots were hybridized sequentially with OA1 genomic
and cDNA probes. Stock DNA samples from probands
OAP-4, OAP-12, OAP-14, OAP-17, and OAP-18 were
severely depleted or degraded, so, for these individuals,
we used (1) older Southern blots (originally made for
linkage analysis) that contained samples from multiple
individuals in each of their pedigrees and (2) very long
exposure times for autoradiography. We also identified
the exonic source of each PstI and TaqI Southern blot
band detected by the OA1 cDNA probes, using exon-
specific genomic probes.
SSCP analysis.—Individual exons were amplified from
each subject, with previously published primers and con-
ditions (Schiaffino et al. 1995), with minor modifications
(details available, on request, from the authors). One
member of each primer pair (∼15% of the total con-
centration for that primer) was end labeled, via T4 ki-
nase, with g-32P-ATP prior to amplification.
For most reactions, we used 50–100 ng of genomic
DNA, 25 pmol of each primer, 125 mM of each dNTP,
and 1.5 mM of MgCl2. For exon 2, primers 516 and
518 (Bassi et al. 1995) were used to analyze a larger
(∼550-bp) PCR product that contains exon 2. For these
reactions, initial denaturation was conducted at 94C
for 4 min. We used a “hot start” cycling protocol with
denaturation at 94C for 1 min, initial annealing tem-
perature of 72C for 1 min, and an extension at 72C
for 3 min, followed by single cycles of 1C decrements
in the annealing temperature, to a final annealing tem-
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Table 1
Subjects and Mutations
Proband
Giant Pigment
Granules Additional Feature(s) Mutation
OAP-1 Present X-linked ichthyosis (STS
deleted)
Missense: A138V(GCArGTA; MwoI site destroyed)
OAP-4 Present Unknown
OAP-6 Absent (by hema-
toxylin-and-eosin
staining)
Deletion: exon 4
OAP-7 Not tested Possibly manifesting female in
pedigree
Splice site: IVS1-1 (agrac; new SnaBI site)
OAP-8 Not tested Dyskeratosis congenita, diabe-
tes, elevated fetal
hemoglobin
Missense: G118E (GGGrGAG)
OAP-9 Absent Frameshift: deletion of 17 bp after base 275 (BssHII site
destroyed)
OAP-10 Present Developmental delay, facial
dysmorphia
Nonsense: amino acid residue 245 (CGArTGA; new BglII site)
OAP-11 Present Developmental delay, renal and
immune dysfunction
Missense: W133R (TGGrCGG; new HpaII/MspI site)
OAP-12 Present Deletion: exon 1
OAP-14 Not tested Deletion: exons 2–8
OAP-17 Present Deletion: exon 2
OAP-18 Present Unknown
OAP-19 Present Deletion: exon 4
OAP-20 Not tested Manifesting female in pedigree:
45,XO
Missense: W133R (TGGrCGG; new HpaII/MspI site)
OAP-21 Not tested Deletion: exons 2–8
OAP-22 Not tested Deletion: exon 2
OAP-23 Not tested Possibly manifesting female in
pedigree
Deletion: exons 2–8
OAP-24 Not tested Possibly manifesting female in
pedigree
Deletion: exons 2–8
OAP-25 Not tested Deletion: exon 1
OAP-26 Present Becker-type muscular dystrophy Missense: S152N (AGCrAAC; DdeI site destroyed)
OAP-27 Not tested Deletion: exons 2–8
OAP-28 Present Mother has normal fundus
exam, mother and affected
grandfather have “vitiligo”
Missense: T232K (ACGrAAG)
OAP-29 Not tested Missense: C116R (TGCrCGC; new BstUI site)
OAP-30 Not tested Mother has photophobia Missense: G84R (GGTrCGT; BstNI site destroyed)
OAP-31 Not tested Proband also has open-angle
glaucoma
Deletion: exon 1
OAP-32 Not tested Frameshift: deletion of base 462 (G)
OAP-33 Not tested Deletion: exons 2–8
OAP-34 Mother only (ab-
sent in OAP-34)
Unknown
OAP-35 Not tested Mother has periodic alternating
nystagmus, photophobia,
high myopia, macular hypo-
plasia, albinotic fundus, iris
transillumination, cleft lip
and palate
Missense: E235K (GAGrAAG)
perature of 62C. The final PCR parameters (94C for
1 min, 62C for 1 min, and 72C for 3 min) were then
repeated for 40 cycles, with a final extension at 72C
for 7 min.
Denatured PCR products were resolved by SSCP
(Orita et al. 1989), in nondenaturing 0.5 # mutation-
detection–electrophoresis gels (MDE [FMC Bioprod-
ucts] ) in 1 # Tris-borate EDTA buffer run at 400 V,
at room temperature, for 16–20 h. Autoradiography of
gels was conducted at 80C for 1–12 h.
For sequencing, PCR products of aberrantly migrating
bands were either gel isolated and purified or cloned into
the TA cloning vector (Invitrogen) for sequencing in both
directions. Sequence analysis was performed by the Nu-
cleic Acid/Protein Research Core Facility at the Chil-
dren’s Hospital of Philadelphia, with an automated Ap-
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Figure 1 Schematic overview of the nine exons of the OA1 gene, in relation to detected deletions and mutations. Coding regions are
denoted by the blackened boxes; and large deletions are denoted by the black bars below the gene. Point mutations are shown above the gene.
plied Biosystems 373 DNA sequencer with ABI’s Prism
Dye Terminator sequencing kit.
Whenever possible, we checked multiple affected in-
dividuals in each pedigree, to reduce the risk of false
“deletions” that might have been due to poor quality of
template DNA. In two families (in individuals OAP-4
and OAP-18), exon 1 mutation screening was incom-
plete because of insufficient stocks of DNA. Polymor-
phism was excluded in a minimum of 132 control mixed-
race X chromosomes for each missense mutation
identified.
Results
Deletion Analysis
We detected large deletions of OA1 in 13 OA pro-
bands (table 1 and fig. 1), using a combination of South-
ern blotting and PCR analysis. There were three dele-
tions of exon 1 (two of which were identical), two of
exon 2, two of exon 4, and six others that spanned exons
2–8.
Figure 2 shows representative deletions detected on a
TaqI Southern blot hybridized with a nearly full-length
OA1 cDNA probe spanning nucleotides 362–1579
(from the middle of exon 2 through exon 9). The blot
was also sequentially hybridized with genomic probes
from individual exons. All males show two additional
faintly hybridizing bands that may be Y specific (denoted
by the asterisks [*] in fig. 2). We postulate this on the
basis of their absence in all females tested, their presence
in affected and unaffected sons of carrier females (in
whom these bands are absent), and their absence in so-
matic-cell hybrids that contain only the X chromosome
(data not shown).
OAP-23 and OAP-33 each have large deletions that
span exons 2–8. OAP-22 has a deletion of exon 2, with
a shifted exon 3 band. OAP-19 and OAP-6 show two
distinct deletions of exon 4, with OAP-6 showing a
shifted exon 5 fragment that comigrates with exon 9, as
a darker band. OAP-31 has a deletion of exon 1 that
extends into intron 1 and that causes shifts in the exon
2/3 TaqI band (described below and detailed in fig. 4).
The highest-molecular-weight band in OAP-31 is also
detected by an exon 1 genomic probe (data not shown).
OAP-32 has a point mutation (see below) and shows no
deletion or band shifts.
Figure 3 shows a PstI Southern blot hybridized with
the same cDNA probe (from the middle of exon 2
through exon 9). With PstI, the probe detects three
bands that appear to be Y specific (denoted by asterisks
[*] in fig. 3). Large deletions that span exons 2–8 are
apparent in OAP-23 and OAP-33. OAP-22 has a dele-
tion involving all of exon 2; the exon 3 band is shifted
downward and comigrates with exon 5. OAP-19 and
OAP-6 have exon 4 deletions with no obviously shifted
bands. The exon 4 deletions are more difficult to detect
than those on the TaqI blot (fig. 2) because exons 4 and
5 correspond to faint, lower-molecular-weight PstI
bands. In OAP-31, with an exon 1 deletion that extends
into intron 1 (also see fig. 4), the exon 2 PstI band is
shifted slightly downward. Both OAP-32 and OAP-30
have point mutations and show no alterations on the
Southern blot.
In addition to OAP-31, two other probands (OAP-25
and OAP-12) were deleted for exon 1. The extent of the
deletion in OAP-25 was not specifically determined;
however, all of exon 2 was spared. OAP-12 and OAP-
31 had identical deletions (fig. 4), as determined by se-
quencing of a PCR-amplification product by primers
6H1F and 6H9 (Bassi et al. 1995; Schiaffino et al. 1995).
The deletions began in the 5′ flanking region just down-
stream of the primer, included a small insertion of six
nucleotides, and ended within intron 1.
SSCP Analysis
Eight new missense mutations (figs. 1 and 5) were
found, in nine unrelated probands. All of these cluster
in exons 1–3 and 6, in putative transmembrane residues
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Figure 2 Southern blot of TaqI-digested DNA from selected OA
probands and controls hybridized with a nearly full-lengthOA1 cDNA
probe, generated from primers OACDNA9 and OACDNA6, that
spans from the middle of exon 2 through exon 9, nucleotides
362–1559. Primer sequences are OACDNA9 (forward, 5′-
GCGTCTCGGATATGAACCACC) and OACDNA6 (reverse, 5′-
CCCCAAGGATGTGGACCTTAC). The blot was also sequentially
hybridized with exon-specific probes, to identify each fragment. The
asterisks (*) denote probable male-specific bands (for details, see the
text). OAP-23 and OAP-33 have large deletions spanning exons 2–8.
OAP-22 has a deletion of exon 2, with a shifted exon 3 band. OAP-
19 and OAP-6 have two distinct deletions of exon 4, with OAP-6
showing a shifted exon 5 fragment that comigrates with exon 9, as a
darker band. OAP-31 has an exon 1 deletion that extends into intron
1, causing a shift in the exon 2/3 TaqI fragment. OAP-32 has a point
mutation and shows a normal pattern.
Figure 3 Southern blot of PstI-digested DNA from selected OA
probands and controls hybridized with OA1 cDNA probe that spans
from the middle of exon 2 through exon 9 (described in fig. 2). This
blot was also sequentially hybridized with exon-specific probes, to
identify each fragment. Asterisks (*) denote probable male-specific
bands (for details, see the text). OAP-23 and OAP-33 have large de-
letions spanning exons 2–8. OAP-22 has an exon 2 deletion; the exon
3 band is shifted down and comigrates with exon 5. OAP-19 and
OAP-6 have exon 4 deletions with no obvious band shifts. (Note that
exons 4 and 5 correspond to faint, lower-molecular-weight PstI bands
and that exon 4 deletions readily detected with TaqI [in fig. 2] are not
readily detected with PstI.) OAP-31 has an exon 1 deletion that extends
into intron 1. There is a slight downward shift of the exon 2 band.
OAP-32 and OAP-30 (who have point mutations) each have a normal
male pattern.
and/or those that are conserved between mouse and man
(Bassi et al. 1996; Newton et al. 1996). There was also
a splice acceptor–site mutation, a nonsense mutation, a
single base deletion leading to a frameshift with pre-
mature termination of translation, and a previously re-
ported 17-bp deletion within exon 1 (Schiaffino et al.
1995). Familial segregation of point mutations was also
studied. Details are outlined below. Specific sequence
changes and altered restriction sites are given in table 1
and in the figure legends.
Exon 1.—In OAP-9, from an Australian-British family,
a deletion of 17 bp within exon 1 produces a frameshift
leading to a premature stop codon. The deletion seg-
regates within the pedigree as shown in figure 5a. This
is a family in which two affected males and one obligate
carrier lacked MMGs on skin biopsy and in which we
previously had performed a prenatal diagnosis, via link-
age analysis, to predict an unaffected male fetus (Schnur
et al. 1994). The identical deletion was reported, in a
British family, by Schiaffino et al. (1995).
In OAP-30, a missense mutation, G84R, was detected
(data not shown). When a BstNI site destroyed by the
mutation was used, the change was absent in 132 normal
X chromosomes. Interestingly, another missense muta-
tion at the same residue, G84D, had been reported pre-
viously by Schiaffino et al. (1995).
Exon 2.—Three point mutations and a polymorphism
were detected in a 550-bp PCR product containing exon
2 and surrounding intronic sequences (primers 516 and
518; Bassi et al. 1995). OAP-7 had a single base change
at the splice acceptor site of IVS1 (agrac) (fig. 5b). All
females tested were heterozygotes, with the exception of
IV-2, who was homozygous for the normal allele. This
clarified genetic counseling for IV-2; we had previously
noted a recombination event between flanking RFLPs
(DXS143 and DXS16; Schnur et al. 1994), which had
prevented determination of IV-2’s carrier status. We ver-
ified absence of this mutation in all other OA males
without a deletion and in 172 control alleles, using the
SnaBI assay shown in figure 5b.
OAP-29 (fig. 5c) had a cysteine-to-arginine substitu-
tion at residue 116. The mutation was excluded in all
other OA probands and in 172 normal alleles, by means
of a mutation-specific BstUI site. At the time when this
mutation was noted in the proband, a carrier female in
this family (II-2) was pregnant with a male fetus and
planned to terminate the pregnancy because of her 50%
risk of transmitting the gene. SSCP and the BstUI assay
were used to test DNA from a chorionic villus sample
(fig. 5c), to predict an affected male. The pregnancy was
terminated at 15 wk gestation; the presence of the mu-
tation was confirmed in DNA from a fetal skin sample
obtained from the abortus material.
In OAP-8, the mutation was a substitution of gluta-
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Figure 4 Summary of the sequence analysis of two unrelated probands (OAP-12 and OAP-31) with identical exon 1 deletions. Primers
6H1F and 6H9 (Bassi et al. 1995; Schiaffino et al. 1995) were used to PCR amplify across these deletions. Sequencing revealed that the deletion
began just 5′ of exon 1 and extended into IVS1. There was also a small insertion, of six bases, at the deletion junction.
mate for glycine at residue 118 (data not shown). One
hundred thirty-two control alleles screened by SSCP
were negative for this alteration. OAP-8, with a normal
46,XY karyotype, also has dyskeratosis congenita (with
20-nail dystrophy and patchy cutaneous hyperpigmen-
tation), elevated levels of fetal hemoglobin, and early-
onset (20 mo) insulin-dependent diabetes mellitus (Rei-
chel et al. 1992; Schnur et al. 1994). However, other
OA males in his family are not affected with these ad-
ditional features. The exon 2 PCR product from another
OA-only affected male in this family was also sequenced;
the identical mutation was found.
We also detected a crg sequence variation within
IVS2, at position 13 (GCG gtg agt cca ccc cctcrGCG
gtg agt cca ccc gctc) in five (17%) of our OA probands
(OAP-7, OAP-8, OAP-12, OAP-18, and OAP-19), all of
whom were Caucasian. Four of these individuals had
other detectable OA1 mutations or deletions. This se-
quence alteration creates a new restriction site for the
enzyme BsrBI (CCG/CTC). Using BsrBI, we then
screened 268 control exon 2 alleles from a set of un-
related, racially mixed but mostly Caucasian females and
normal males. We detected only seven control alleles
(2.6%) with this change.
Exon 3.—The segregation of three different mutations
within four families (in individuals OAP-20, OAP-26,
OAP-11, and OAP-1) is shown in figure 5d. In three of
these families, probands had nonocular phenotypic fea-
tures in addition to OA.
Two probands not known to be related to each
other—OAP-11 and OAP-20—had the same mutation,
W133R. OAP-11 has OA with MMGs and also has
developmental delay and renal and immune dysfunction;
the pedigree of OAP-20 is notable for containing a
45,XO female who has OA. W133R was not present in
182 control X chromosomes.
OAP-26, who is the only individual with OA in his
family, also has Becker-type muscular dystrophy. Dys-
trophin immunofluorescence was absent on muscle bi-
opsy; however, the individual did not have a detectable
dystrophin mutation, on the basis of standard techniques
and computer-assisted laser densitometry (P. Ray, per-
sonal communication). The proband had typical
MMGs, but his mother and sister had “questionable”
pigmentary mottling of their fundi. Figure 5d confirms
that the mother is clearly a carrier of the S152N mu-
tation; the sister is homozygous for the normal allele.
S152N was excluded in 182 control alleles.
OAP-1 belongs to an African American pedigree in
which a deletion of the steroid sulfatase gene (STS) co-
segregates with OA (Schnur et al. 1990, 1991, 1994).
Although the family’s alanine-to-valine (A138V) muta-
tion seems to be conservative, on the basis of the MwoI
site abolished by the mutation, polymorphism was ex-
cluded in 222 alleles, including x50 alleles known to
be of African American origin.
OAP-32 was an apparently isolated case within his
family, whose mother had funduscopic changes char-
acteristic of an OA carrier. He had a single base deletion
of a G at position 462, which leads to a frameshift and
premature termination of translation (data not shown).
Exon 6.—OAP-10 had a nonsense mutation (fig. 5e).
At least two boys in this Australian kindred have de-
velopmental delay and facial dysmorphia plus OA with
MMGs. Mutation analysis using a mutation-specific
BglII site shows that the female represented in lane 8 of
figure 5e is not a carrier.
OAP-28 had a unique missense mutation, T232K (not
shown). This change was not present in 192 control X
chromosomes. The mother of the proband is an oblig-
atory carrier but had a normal funduscopic exam. She
and her father (who is affected with OA) are both re-
ported to have depigmented patches of skin.
OAP-35 had a missense mutation, E235K (data not
Figure 5 Family studies. a, Segregation of a 17-bp deletion (275del17) within exon 1 in the pedigree of OAP-9. The PCR products were
amplified by primers 6H1BF2 and 6H1BR2 (Schiaffino et al. 1995) and were resolved by horizontal electrophoresis in 3% NuSieve agarose
gels (FMC Bioproducts) in 1# Tris-borate EDTA buffer. The female represented in lane 2 is verified to be a carrier, and the female represented
in lane 12 is not a carrier. b, Segregation of the IVS2 splice acceptor–site mutation in pedigree 7. The mutation creates a new restriction site
for SnaBI, which cleaves the 550-bp exon 2 PCR product (primers 516 and 518) into two fragments (∼360 bp and ∼190 bp). Both the proband
(IV-4) and his affected cousin (IV-1) are hemizygous for the mutation. For the females in the family, results of this assay were consistent with
our previous linkage analysis (Schnur et al. 1994), showing that, with the exception of IV-2, who was homozygous for the normal allele, all
females tested were heterozygotes. c, Segregation of the C116R mutation in the pedigree of OAP-29, and prenatal diagnosis of an affected
male. Top, SSCP analysis of exon 2 (primers 516 and 518 [Bassi et al. 1995] in an 0.5 # MDE gel). DNA from II-1 was not available for this
study. DNA from the male fetus (III-3) in the pregnancy at risk shows the same shifted pattern as is seen in the affected cousin (III-1). Bottom,
Confirmation of the mutation by BstUI digestion of the exon 2 PCR products. The new restriction site created by the mutation cleaves the 550-
bp product into two fragments (∼500 bp and ∼50 bp) in III-1 and III-3 and in a heterozygous pattern in the carrier female II-2. d, Exon 3
SSCP analysis (0.5 # MDE gel; FMC Bioproducts), showing segregation of the mutations in four families. Three of these four families contain
probands (OAP26, OAP-11, and OAP-1) who have variant phenotypes. Mutations detected are W133R in both OAP-20 and OAP-11 (OA
plus developmental delay and renal and immune dysfunction), S152N in OAP-26 (OA plus Becker-type muscular dystrophy), and A138V in
OAP-1 (OA plus X-linked ichthyosis/STS deletion). The analysis confirms that the mother of OAP-26 is a carrier but that the sister is not. e,
Segregation of the R245STOP mutation in the family of OAP-10. The proband has OA plus developmental delay and facial dysmorphia. The
mutation creates a new restriction site for BglII. The female represented in lane 8 is confirmed to be homozygous for the normal allele.
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shown); the mutation was excluded in 132 control X
chromosomes. By history, the mother of the proband is
a manifesting heterozygote (see table 1) with fundus-
copic features of a fully affected hemizygote. She has
periodic alternating nystagmus, which is not typical of
albinism and was not present in her son. She also has a
cleft lip and palate.
Discussion
When Schiaffino et al. (1995) screened the entireOA1
coding sequence, they detected mutations in only one-
third of their patient group. Mutations included five in-
tragenic deletions (four of exon 2 and one of exons 4–8),
two smaller deletions (a single-amino-acid deletion and
a 17-bp deletion), one splice-site mutation, four missense
mutations (two in predicted transmembrane domains),
and two insertions leading to frameshifts. Three muta-
tions were observed in more than one unrelated family
that shared a common ethnic origin.
Our own studies detected a relatively higher frequency
(∼90%) of large deletions (13 cases) and/or smaller mu-
tations (13 cases) of the OA1 gene, in 29 clinically well-
characterized individuals with X-linked OA. Our sub-
jects and their mutations are summarized in table 1 and
figure 1.
All of the large deletions are intragenic (fig. 1), with
the possible exception of the deletion in OAP-25; this
may extend 5′ of the gene, but this has not yet been
verified. OAP-12 and OAP-31 had apparently identical
deletions of exon 1 (figs. 1 and 4) but are not known
to be related to each other. The exon 2–only deletions
that we detected (in OAP-17 and OAP-22) may have
arisen by a mechanism similar to that reported by Schiaf-
fino et al. (1995), which involved homologous but un-
equal recombination between two of three regionalALU
sequences. However, we have not been able to verify
this, because we were not able to amplify across either
of these deletions, with any of several different primer
sets. Exons 4 and 8 may also represent deletional hot
spots of this kind. We detected six patients with deletions
that are larger than any previously reported, spanning
exons 2–8. The individuals who carry these large dele-
tions are not known to be related to each other; however,
four of these families were all referred from the south-
eastern part of the United States.
We had postulated that large OA1 deletions, possibly
involving contiguous genes, might underlie mutations in
five OA probands (in OAP-1, OAP-8, OAP-10, OAP-
11, and OAP-26; see table 1), a group with OA plus
nonocular phenotypic features, but we detected OA1
point mutations in all five probands in this group. Cu-
riously, several of the nonocular phenotypes are also
expected to be caused by mutations in other X-linked
genes—for example, the confirmed deletion of STS in
OA1-1 (Schnur et al. 1989), the dyskeratosis congenita
seen in OAP-8 (Reichel et al. 1992), and the Becker-type
muscular dystrophy seen in OAP-26. However, it now
seems likely that most, if not all, of the complex phe-
notypes are coincidental.
In general, genotype-phenotype correlation seems to
be poor. All probands with large OA1 deletions had
typical OA, without additional nonocular features (table
1). Two individuals (OAP-23 and OAP-24) with dele-
tions that spanned exons 2–8 had female relatives with
a history of nystagmus and significant visual impairment
(these individuals were not available for formal oph-
thalmoscopic examination). OAP-12 (exon 1 deletion),
OAP-17 (exon 2 deletion), and OAP-19 (exon 4 dele-
tion) came from pedigrees in which one affected male
was documented, on a skin biopsy, to have typical giant
pigment granules. However, the one male tested from
OAP-6 (exon 4 deletion) did not have MMGs detectable
by light microscopy (electron-microscopy studies were
not performed).
The newly reported mutations include a splice accep-
tor–site mutation, which is likely to result in exon skip-
ping, and a single base deletion in exon 3, which leads
to a frameshift and premature termination of transla-
tion. We found eight new missense substitutions; six lie
within the first three predicted transmembrane domains
of the protein (Schiaffino et al. 1995), and the other two
(T232K and E235 K) lie within conserved residues (Bassi
et al. 1996). In the future, direct assays of the in vivo
and in vitro effects of these mutations on the OA1 tran-
script and protein would greatly contribute to the un-
derstanding of the pathophysiology of the disease.
We detected a polymorphic variant, IVS213 (crg),
with a somewhat higher frequency (∼17%) among OA
chromosomes than among normal chromosomes
(2.6%). Although all five probands who carry IVS213
(crg) are Caucasian, they are from diverse geographic
areas in the United States and Canada and are not
known to be related to each other. In addition, since at
least four of these five probands had other distinct mu-
tations, these results cannot be readily explained by link-
age disequilibrium, unless the polymorphism is a pre-
disposing factor for mutagenesis of the OA1 gene.
Functional assays of this variant will be necessary to
assess its significance, if any. IVS213 (crg) is at least
an easily detected, potentially useful polymorphism for
linkage analysis in X-linked OA families in which mu-
tations are not readily identified.
During the course of this study, we provided prenatal
diagnosis based on specific mutational analysis in a male
fetus at 50% risk for inheritance of OA. Because the
disability in OA is usually limited to visual acuity, few
families are likely to seek out this service. The carrier
aunt of OAP-29 perceived this disease as such an enor-
mous burden that she had chosen to terminate all male
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fetuses. Thus, in some families, prenatal diagnosis can
“salvage” 50% of the male fetuses of carrier females.
Scrotal skin from the aborted 15-wk fetus in the ped-
igree of OAP-29 was examined histologically, but no
giant pigment granules were detected. However, mela-
nocytes first appear in human fetal skin at 40–50 d ges-
tation (Holbrook et al. 1989), and tyrosinase activity is
present only in trace amounts in skin specimens other
than those from the scalp, as assayed in even-later-stage
(17-wk-old) fetuses (Gershoni-Baruch et al. 1991). Thus,
we would not necessarily expect to see highly melanized
giant pigment granules at 15 wk gestation. Therefore,
fetal skin biopsy for the purpose of prenatal diagnoses
of OA would be expected to be unreliable. In addition,
we elsewhere had noted variability of this finding among
living OA probands (Schnur et al. 1994). It should be
noted that none of the other living gene carriers in the
family of OAP-29 had had skin biopsies performed to
verify the presence or absence of this trait.
On the basis of our study’s high rate of detected mu-
tations within the OA1 gene, we can conclude that (1)
OA1 is the major locus for X-linked OA, (2) OA1 mu-
tations show poor genotype-phenotype correlation, (3)
there is a high frequency (45%) of large intragenic de-
letions, and (4) a significant proportion of missense mu-
tations cluster in exons 1–3 and 6 (Schiaffino et al. 1995;
present study). We have also demonstrated the utility of
OA1 mutational analysis in the genetic counseling of
families with this disorder.
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